ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen To Buy Mustafa Nevzat For $700 Million

Biotechnology firm Amgen (AMGN) will buy a 95.6% stake in Mustafa Nevzat Pharmaceuticals for $700 million, in a move to expand its presence in Turkey and the surrounding region. The all-cash transaction has been approved by both the boards, the two companies said in a joint statement Wednesday. MN, which supplies pharmaceuticals to the hospital sector and is a major supplier of injectable medicines in Turkey, had revenue of approximately $200 million in 2011, the statement said. Amgen's focus on Turkey and the surrounding region, which are large, fast-growing, priority markets for Amgen, is a part of its international expansion strategy. Amgen established an affiliate in Turkey in 2010 and currently markets two products, with plans to develop its pipeline of clinical candidates for Turkey and other markets around the world. Order free Annual Report for Amgen, Inc. Visit http://djnewswires.ar.wilink.com/?link=AMGN or call 1-888-301-0513

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
12/02/201616:00:00Amgen Announces Launch Of Blood Counts™ And Collaboration With S...
12/02/201609:00:00Amgen And Allergan Submit Biosimilar Marketing Authorization...
12/01/201616:00:00Amgen To Present At The Citi 2016 Global Healthcare Conference
11/30/201618:31:00The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv...
11/30/201618:30:00The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv...
11/30/201610:00:00Amgen Announces Presentation Of New Data In Acute Lymphoblastic...
11/16/201616:30:00Amgen Announces Erenumab Significantly Reduces Monthly Migraine...
11/15/201616:00:00Amgen And Allergan Submit Biosimilar Biologics License Application...
11/15/201612:28:00Repatha® (Evolocumab) Regresses Atherosclerosis In Patients...
11/14/201609:00:00New 'Ten To Watch' List Highlights Top Amgen Scholars Poised...
11/12/201616:30:00Results From Phase 3 BRIDGE Study Show Romosozumab Significantly...
11/11/201616:00:00European Commission Approves Parsabiv™ (etelcalcetide) For T...
11/10/201616:00:00Amgen To Webcast Investor Meeting At Upcoming American Heart...
11/10/201608:33:00Amgen Announces Collaboration With Janssen To Co-Fund Studies...
11/07/201616:00:00Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's...
11/04/201617:26:00FDA Approves Expanded Use Of ENBREL® (etanercept) To Treat Children...
11/04/201608:50:00Regeneron Revenue Growth Slows
11/03/201617:25:27Statement of Changes in Beneficial Ownership (4)
11/03/201616:01:00Amgen To Present At The Credit Suisse 25th Annual Healthcare...
11/02/201609:00:00Amgen Appoints Lori Johnston As Senior Vice President, Human...

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US